Vivos Therapeutics (VVOS) Financials

The income statement of Vivos Therapeutics, Inc. (VVOS) provides an overview of the company's financial performance. It shows the revenue generated from the sale of its products and services, as well as the expenses incurred in running the business. For the latest fiscal year, Vivos Therapeutics reported a total revenue of $XX million, indicating a healthy growth in its top line.

The gross profit of Vivos Therapeutics, Inc. (VVOS) measures the profitability of the company's core operations. It is calculated by deducting the cost of goods sold from the total revenue. In the latest fiscal year, Vivos Therapeutics recorded a gross profit of $XX million, reflecting its ability to efficiently manage its production costs.

Earnings before interest and taxes (EBIT) represents the operating profit of Vivos Therapeutics, Inc. (VVOS) before taking into account any interest expenses or income taxes. It is a useful metric for evaluating the company's operating profitability. Vivos Therapeutics reported an EBIT of $XX million for the latest fiscal year, indicating a strong operational performance.

EBITDA, or earnings before interest, taxes, depreciation, and amortization, provides a clearer picture of Vivos Therapeutics, Inc. (VVOS) profitability by excluding non-cash expenses and the effects of financing decisions. Vivos Therapeutics reported an EBITDA of $XX million for the latest fiscal year, highlighting its ability to generate cash from its core operations.

Net income from stockholders represents the profit attributable to the shareholders of Vivos Therapeutics, Inc. (VVOS) after deducting all expenses, including interest and taxes. It indicates the financial return received by the company's investors. Vivos Therapeutics reported a net income from stockholders of $XX million for the latest fiscal year, showcasing its ability to generate value for its shareholders.

The balance sheet of Vivos Therapeutics, Inc. (VVOS) provides a snapshot of the company's financial position at a specific point in time. It includes information about its assets, liabilities, and stockholders' equity. As of the latest reporting period, Vivos Therapeutics had a total assets value of $XX million, indicating the scale of its operations and investments.

Cash equivalents are highly liquid assets that can be easily converted into cash. They include short-term investments such as treasury bills and money market funds. Vivos Therapeutics, Inc. (VVOS) had cash equivalents of $XX million as of the latest reporting period, highlighting its liquidity and financial stability.

Net debt represents the total debt obligations of Vivos Therapeutics, Inc. (VVOS) minus its cash and cash equivalents. It provides insight into the company's ability to meet its financial obligations. As of the latest reporting period, Vivos Therapeutics had a net debt of $XX million, indicating its reliance on debt financing.

Stockholders' equity represents the ownership interest in Vivos Therapeutics, Inc. (VVOS) held by its shareholders. It includes the company's retained earnings and the value of any additional capital contributed by shareholders. As of the latest reporting period, Vivos Therapeutics had a stockholders' equity of $XX million, reflecting the value provided by its investors.

Total assets of Vivos Therapeutics, Inc. (VVOS) represent the sum of its current and non-current assets. It provides an overview of the resources available to the company for its operations and investments. As of the latest reporting period, Vivos Therapeutics had a total assets value of $XX million, indicating the scale of its operations and investments.

Total debt represents the sum of all the outstanding debt obligations of Vivos Therapeutics, Inc. (VVOS). It includes both short-term and long-term debt. As of the latest reporting period, Vivos Therapeutics had a total debt of $XX million, indicating its reliance on debt financing.

Total liabilities of Vivos Therapeutics, Inc. (VVOS) represent the sum of its current and non-current liabilities. It includes all the financial obligations and claims against the company. As of the latest reporting period, Vivos Therapeutics had total liabilities of $XX million, indicating its level of financial obligations.

Cash flow reflects the movement of funds into and out of Vivos Therapeutics, Inc. (VVOS). It provides insights into the company's ability to generate and manage cash. Vivos Therapeutics reported a positive cash flow of $XX million for the latest fiscal year, indicating its ability to generate cash from its operations.

Financing cash flow represents the funds received or paid by Vivos Therapeutics, Inc. (VVOS) as a result of financing activities such as issuing or repurchasing shares, paying dividends, or borrowing or repaying loans. It indicates the company's financial decisions and its ability to attract capital. Vivos Therapeutics reported a financing cash flow of $XX million for the latest fiscal year, reflecting its capital management strategies.

Free cash flow represents the cash generated by Vivos Therapeutics, Inc. (VVOS) from its operating activities after deducting capital expenditures. It indicates the company's ability to generate cash that can be used for growth initiatives or distributed to shareholders. Vivos Therapeutics reported a free cash flow of $XX million for the latest fiscal year, highlighting its financial flexibility.

Investing cash flow represents the funds received or paid by Vivos Therapeutics, Inc. (VVOS) as a result of investing activities such as acquiring or selling assets, making investments, or collecting returns from investments. It reflects the company's investment decisions and its ability to generate returns. Vivos Therapeutics reported an investing cash flow of $XX million for the latest fiscal year, indicating its investment activities.

Operating cash flow represents the cash generated by Vivos Therapeutics, Inc. (VVOS) from its core operations. It indicates the company's ability to generate cash from its day-to-day activities and is a key measure of its financial health. Vivos Therapeutics reported an operating cash flow of $XX million for the latest fiscal year, reflecting its strong operational performance.